127 related articles for article (PubMed ID: 38189408)
21. MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in
Feriancikova B; Feglarova T; Krskova L; Eckschlager T; Vicha A; Hrabeta J
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806217
[TBL] [Abstract][Full Text] [Related]
22. Downregulation of Axl in non-MYCN amplified neuroblastoma cell lines reduces migration.
Duijkers FA; Meijerink JP; Pieters R; van Noesel MM
Gene; 2013 May; 521(1):62-8. PubMed ID: 23523856
[TBL] [Abstract][Full Text] [Related]
23. High anaplastic lymphoma kinase immunohistochemical staining in neuroblastoma and ganglioneuroblastoma is an independent predictor of poor outcome.
Duijkers FAM; Gaal J; Meijerink JPP; Admiraal P; Pieters R; de Krijger RR; van Noesel MM
Am J Pathol; 2012 Mar; 180(3):1223-1231. PubMed ID: 22203052
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
Marrano P; Irwin MS; Thorner PS
Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
[TBL] [Abstract][Full Text] [Related]
25. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
[TBL] [Abstract][Full Text] [Related]
26. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry.
Nagai J; Ishida Y; Koga N; Tanaka Y; Ohnuma K; Toyoda Y; Katoh A; Hayabuchi Y; Kigasawa H
J Pediatr Hematol Oncol; 2000; 22(1):20-6. PubMed ID: 10695817
[TBL] [Abstract][Full Text] [Related]
27. Risk stratification of high-risk metastatic neuroblastoma: A report from the HR-NBL-1/SIOPEN study.
Morgenstern DA; Pötschger U; Moreno L; Papadakis V; Owens C; Ash S; Pasqualini C; Luksch R; Garaventa A; Canete A; Elliot M; Wieczorek A; Laureys G; Kogner P; Malis J; Ruud E; Beck-Popovic M; Schleiermacher G; Valteau-Couanet D; Ladenstein R
Pediatr Blood Cancer; 2018 Nov; 65(11):e27363. PubMed ID: 30015396
[TBL] [Abstract][Full Text] [Related]
28. Detection of MYCN DNA in the cerebrospinal fluid for diagnosing isolated central nervous system relapse in neuroblastoma.
Kimoto T; Inoue M; Tokimasa S; Yagyu S; Iehara T; Hosoi H; Kawa K
Pediatr Blood Cancer; 2011 May; 56(5):865-7. PubMed ID: 21370425
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of bortezomib in combination with irinotecan in patients with relapsed/refractory high-risk neuroblastoma.
Mody R; Zhao L; Yanik GA; Opipari V
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28436582
[TBL] [Abstract][Full Text] [Related]
30. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
Wang M; Zhou C; Cai R; Li Y; Gong L
Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
[TBL] [Abstract][Full Text] [Related]
31. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
Weber A; Starke S; Bergmann E; Christiansen H
Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
[TBL] [Abstract][Full Text] [Related]
32. Neuroblastoma progress on many fronts: the Neuroblastoma Research Symposium.
Wylie L; Philpott A
Pediatr Blood Cancer; 2012 Apr; 58(4):649-51. PubMed ID: 21922652
[TBL] [Abstract][Full Text] [Related]
33. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.
Castle VP; Heidelberger KP; Bromberg J; Ou X; Dole M; Nuñez G
Am J Pathol; 1993 Dec; 143(6):1543-50. PubMed ID: 8256847
[TBL] [Abstract][Full Text] [Related]
34. Antitumor Activity and Tolerability of hu14.18-IL2 with GMCSF and Isotretinoin in Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Phase II Study.
Shusterman S; Naranjo A; Van Ryn C; Hank JA; Parisi MT; Shulkin BL; Servaes S; London WB; Shimada H; Gan J; Gillies SD; Maris JM; Park JR; Sondel PM
Clin Cancer Res; 2019 Oct; 25(20):6044-6051. PubMed ID: 31358541
[TBL] [Abstract][Full Text] [Related]
35. Back to the future: evolutionary biology reveals a key regulatory switch in neuroblastoma pathogenesis.
Wertman JN; Berman JN
J Clin Invest; 2023 May; 133(10):. PubMed ID: 37183823
[TBL] [Abstract][Full Text] [Related]
36. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
[TBL] [Abstract][Full Text] [Related]
37. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
[TBL] [Abstract][Full Text] [Related]
38. Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma.
García-López J; Wallace K; Otero JH; Olsen R; Wang YD; Finkelstein D; Gudenas BL; Rehg JE; Northcott P; Davidoff AM; Freeman KW
Cell Rep; 2020 Jan; 30(2):454-464.e5. PubMed ID: 31940489
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.
Asgharzadeh S; Salo JA; Ji L; Oberthuer A; Fischer M; Berthold F; Hadjidaniel M; Liu CW; Metelitsa LS; Pique-Regi R; Wakamatsu P; Villablanca JG; Kreissman SG; Matthay KK; Shimada H; London WB; Sposto R; Seeger RC
J Clin Oncol; 2012 Oct; 30(28):3525-32. PubMed ID: 22927533
[TBL] [Abstract][Full Text] [Related]
40. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
